Report cover image

Global Human Rabies Vaccines Market Size study, by Cell Line Type, Application, Route of Administration, End-Users, Distribution Channel and Regional Forecasts 2022-2032

Publisher Bizwit Research & Consulting
Published May 30, 2025
Length 285 Pages
SKU # BIZW20057043

Description

Global Human Rabies Vaccines Market is valued approximately at USD 1.01 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 4.70% over the forecast period 2024-2032. Human rabies vaccines represent a cornerstone in the fight against one of the world’s most fatal yet preventable viral diseases. Designed primarily for post-exposure prophylaxis but also used for pre-exposure immunization in high-risk populations, these vaccines function by stimulating the immune system to produce virus-neutralizing antibodies. Traditionally derived from various cell substrates such as chick embryo cells, Vero cells, and BHK cells, rabies vaccines have undergone remarkable advancements in terms of efficacy, tolerability, and safety. Amid heightened awareness, robust global eradication initiatives, and broader distribution channels, the human rabies vaccines market is witnessing a paradigm shift toward more accessible, innovative, and long-acting immunization solutions.

The growing burden of animal bites, particularly in densely populated and rural regions with poor access to medical care, continues to be a key driver propelling market expansion. Rising public health campaigns, enhanced surveillance, and increased inclusion of rabies vaccines in national immunization schedules are significantly augmenting demand. Additionally, the increasing prevalence of stray dog populations in emerging economies, combined with global travel and migration trends, is elevating the risk of rabies exposure. Pharmaceutical manufacturers are increasingly leveraging recombinant technologies, exploring thermostable vaccine formulations, and investing in next-generation delivery mechanisms such as micro-needles and intradermal injectables to improve coverage and compliance. These technological innovations are reshaping market dynamics by reducing dependency on cold chain logistics and making vaccines more affordable and adaptable in resource-constrained environments.

While the market outlook remains promising, several challenges persist. Limited healthcare infrastructure in rural and low-income regions often restricts timely vaccine administration, exacerbating morbidity and mortality rates. Moreover, vaccine hesitancy, particularly in areas plagued by misinformation and cultural taboos, undermines immunization efforts. High manufacturing costs, coupled with complex regulatory pathways for novel cell-based vaccines, may hinder the pace of new product development. Nevertheless, cross-sector collaborations between governments, NGOs, and private sector players are addressing these barriers through subsidized pricing models, donation programs, and extensive awareness campaigns aimed at enhancing accessibility and uptake.

The evolution of distribution models is a vital aspect of the market's growth trajectory. Hospital pharmacies continue to lead due to their close association with emergency care units, but retail pharmacies and online platforms are rapidly gaining momentum. The digitalization of supply chains, integration of cold storage tech, and improved inventory tracking are enhancing vaccine reach and reliability. In terms of administration, the preference is shifting toward intradermal and subcutaneous routes for their lower dosage requirements and ease of delivery, particularly in mass immunization drives. Additionally, a growing inclination toward outpatient treatment options is amplifying the role of specialty clinics and even homecare settings, offering patients greater flexibility and convenience.

From a regional standpoint, Asia Pacific dominates the global human rabies vaccines market, primarily due to a disproportionately high number of rabies-related deaths reported in countries like India, China, and the Philippines. Regional governments are actively rolling out strategic intervention programs and bolstering vaccine production capacities. North America and Europe hold substantial market shares as well, driven by robust R&D pipelines, stringent animal control regulations, and the presence of leading pharmaceutical manufacturers. Meanwhile, Latin America and the Middle East & Africa are showing growing demand on the back of increasing cross-border veterinary surveillance, enhanced access to healthcare, and targeted immunization initiatives supported by international organizations.

Major market player included in this report are:
• Sanofi S.A.
• Bharat Biotech International Limited
• Cadila Healthcare Ltd (Zydus Cadila)
• Serum Institute of India Pvt. Ltd.
• GlaxoSmithKline plc
• Merck & Co., Inc.
• Novartis AG
• Pfizer Inc.
• Boehringer Ingelheim International GmbH
• Bio-Med Pvt. Ltd.
• Guangdong WINSUN Bio-Pharmaceutical Co., Ltd.
• Changchun Institute of Biological Products Co., Ltd.
• Yisheng Biopharma Co., Ltd.
• Indian Immunologicals Ltd.
• Vins Bioproducts Ltd.

The detailed segments and sub-segmens of the market are explained below:

By Cell Line Type
• Chick Embryo Cells
• Vero Cell
• BHK Cells
• Others

By Application
• Pre Exposure Prophylaxis
• Post Exposure Prophylaxis

By Route of Administration
• Intravenous
• Subcutaneous

By End-Users
• Hospitals
• Homecare
• Specialty Clinics
• Others

By Distribution Channel
• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

By Region:

North America
• U.S.
• Canada

Europe
• UK
• Germany
• France
• Spain
• Italy
• Rest of Europe

Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• Rest of Asia Pacific

Latin America
• Brazil
• Mexico

Middle East & Africa
• Saudi Arabia
• South Africa
• Rest of Middle East & Africa

Years considered for the study are as follows:
• Historical year – 2022
• Base year – 2023
• Forecast period – 2024 to 2032

Key Takeaways:
• Market Estimates & Forecast for 10 years from 2022 to 2032.
• Annualized revenues and regional level analysis for each market segment.
• Detailed analysis of geographical landscape with Country level analysis of major regions.
• Competitive landscape with information on major players in the market.
• Analysis of key business strategies and recommendations on future market approach.
• Analysis of competitive structure of the market.
• Demand side and supply side analysis of the market.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.

Table of Contents

285 Pages
Chapter 1. Global Human Rabies Vaccines Market Executive Summary
1.1. Global Human Rabies Vaccines Market Size & Forecast (2022–2032)
1.2. Regional Summary
1.3. Segmental Summary
1.3.1. By Cell Line Type
1.3.2. By Application
1.3.3. By Route of Administration
1.3.4. By End-Users
1.3.5. By Distribution Channel
1.4. Key Trends
1.5. Recession Impact
1.6. Analyst Recommendation & Conclusion
Chapter 2. Global Human Rabies Vaccines Market Definition and Research Assumptions
2.1. Research Objective
2.2. Market Definition
2.3. Research Assumptions
2.3.1. Inclusion & Exclusion
2.3.2. Limitations
2.3.3. Supply Side Analysis
2.3.3.1. Availability
2.3.3.2. Infrastructure
2.3.3.3. Regulatory Environment
2.3.3.4. Market Competition
2.3.3.5. Economic Viability (Consumer’s Perspective)
2.3.4. Demand Side Analysis
2.3.4.1. Regulatory Frameworks
2.3.4.2. Technological Advancements
2.3.4.3. Environmental Considerations
2.3.4.4. Consumer Awareness & Acceptance
2.4. Estimation Methodology
2.5. Years Considered for the Study
2.6. Currency Conversion Rates
Chapter 3. Global Human Rabies Vaccines Market Dynamics
3.1. Market Drivers
3.1.1. Rising Incidence of Animal Bites and Rabies Exposure
3.1.2. Expansion of National Immunization Programs
3.1.3. Advances in Cell Culture and Recombinant Vaccine Technologies
3.2. Market Challenges
3.2.1. Cold-Chain Logistics Constraints in Remote Regions
3.2.2. Vaccine Hesitancy and Misinformation
3.3. Market Opportunities
3.3.1. Development of Thermostable and Intradermal Formulations
3.3.2. Growth of Online Pharmacy and Direct-to-Patient Models
3.3.3. Public-Private Partnerships for Subsidized Vaccination
Chapter 4. Global Human Rabies Vaccines Market Industry Analysis
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter’s 5 Forces
4.1.7. Porter’s 5 Forces Impact Analysis
4.2. PESTEL Analysis
4.2.1. Political
4.2.2. Economical
4.2.3. Social
4.2.4. Technological
4.2.5. Environmental
4.2.6. Legal
4.3. Top Investment Opportunity
4.4. Top Winning Strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspective
4.7. Analyst Recommendation & Conclusion
Chapter 5. Global Human Rabies Vaccines Market Size & Forecasts by Cell Line Type 2022–2032
5.1. Segment Dashboard
5.2. Global Human Rabies Vaccines Market: Cell Line Type Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)
5.2.1. Chick Embryo Cells
5.2.2. Vero Cell
5.2.3. BHK Cells
5.2.4. Others
Chapter 6. Global Human Rabies Vaccines Market Size & Forecasts by Application 2022–2032
6.1. Segment Dashboard
6.2. Global Human Rabies Vaccines Market: Application Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)
6.2.1. Pre-Exposure Prophylaxis
6.2.2. Post-Exposure Prophylaxis
Chapter 7. Global Human Rabies Vaccines Market Size & Forecasts by Route of Administration 2022–2032
7.1. Segment Dashboard
7.2. Global Human Rabies Vaccines Market: Route of Administration Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)
7.2.1. Intravenous
7.2.2. Subcutaneous
Chapter 8. Global Human Rabies Vaccines Market Size & Forecasts by End-Users 2022–2032
8.1. Segment Dashboard
8.2. Global Human Rabies Vaccines Market: End-Users Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)
8.2.1. Hospitals
8.2.2. Homecare
8.2.3. Specialty Clinics
8.2.4. Others
Chapter 9. Global Human Rabies Vaccines Market Size & Forecasts by Distribution Channel 2022–2032
9.1. Segment Dashboard
9.2. Global Human Rabies Vaccines Market: Distribution Channel Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)
9.2.1. Hospital Pharmacy
9.2.2. Online Pharmacy
9.2.3. Retail Pharmacy
Chapter 10. Global Human Rabies Vaccines Market Size & Forecasts by Region 2022–2032
10.1. North America Human Rabies Vaccines Market
10.1.1. U.S. Human Rabies Vaccines Market
10.1.1.1. Cell Line Type breakdown size & forecasts, 2022–2032
10.1.1.2. Application breakdown size & forecasts, 2022–2032
10.1.1.3. Route of Administration breakdown size & forecasts, 2022–2032
10.1.1.4. End-Users breakdown size & forecasts, 2022–2032
10.1.1.5. Distribution Channel breakdown size & forecasts, 2022–2032
10.1.2. Canada Human Rabies Vaccines Market
10.2. Europe Human Rabies Vaccines Market
10.2.1. UK
10.2.2. Germany
10.2.3. France
10.2.4. Spain
10.2.5. Italy
10.2.6. Rest of Europe
10.3. Asia Pacific Human Rabies Vaccines Market
10.3.1. China
10.3.2. India
10.3.3. Japan
10.3.4. Australia
10.3.5. South Korea
10.3.6. Rest of Asia Pacific
10.4. Latin America Human Rabies Vaccines Market
10.4.1. Brazil
10.4.2. Mexico
10.4.3. Rest of Latin America
10.5. Middle East & Africa Human Rabies Vaccines Market
10.5.1. Saudi Arabia
10.5.2. South Africa
10.5.3. Rest of Middle East & Africa
Chapter 11. Competitive Intelligence
11.1. Key Company SWOT Analysis
11.1.1. Sanofi S.A.
11.1.2. Merck & Co., Inc.
11.1.3. GlaxoSmithKline plc
11.2. Top Market Strategies
11.3. Company Profiles
11.3.1. Sanofi S.A.
11.3.1.1. Key Information
11.3.1.2. Overview
11.3.1.3. Financial (Subject to Data Availability)
11.3.1.4. Product Summary
11.3.1.5. Market Strategies
11.3.2. Bharat Biotech International Limited
11.3.3. Cadila Healthcare Ltd (Zydus Cadila)
11.3.4. Serum Institute of India Pvt. Ltd.
11.3.5. GlaxoSmithKline plc
11.3.6. Merck & Co., Inc.
11.3.7. Novartis AG
11.3.8. Pfizer Inc.
11.3.9. Boehringer Ingelheim International GmbH
11.3.10. Bio-Med Pvt. Ltd.
11.3.11. Guangdong WINSUN Bio-Pharmaceutical Co., Ltd.
11.3.12. Changchun Institute of Biological Products Co., Ltd.
11.3.13. Yisheng Biopharma Co., Ltd.
11.3.14. Indian Immunologicals Ltd.
11.3.15. Vins Bioproducts Ltd.
Chapter 12. Research Process
12.1. Research Process
12.1.1. Data Mining
12.1.2. Analysis
12.1.3. Market Estimation
12.1.4. Validation
12.1.5. Publishing
12.2. Research Attributes
List of Tables
TABLE 1. Global Human Rabies Vaccines market, report scope
TABLE 2. Global Human Rabies Vaccines market estimates & forecasts by Region 2022–2032 (USD Million/Billion)
TABLE 3. Global Human Rabies Vaccines market estimates & forecasts by Cell Line Type 2022–2032 (USD Million/Billion)
TABLE 4. Global Human Rabies Vaccines market estimates & forecasts by Application 2022–2032 (USD Million/Billion)
TABLE 5. Global Human Rabies Vaccines market estimates & forecasts by Route of Administration 2022–2032 (USD Million/Billion)
TABLE 6. Global Human Rabies Vaccines market estimates & forecasts by End-Users 2022–2032 (USD Million/Billion)
TABLE 7. Global Human Rabies Vaccines market estimates & forecasts by Distribution Channel 2022–2032 (USD Million/Billion)
TABLE 8. Global Human Rabies Vaccines market by segment, estimates & forecasts, 2022–2032 (USD Million/Billion)
TABLE 9. U.S. Human Rabies Vaccines market estimates & forecasts, 2022–2032 (USD Million/Billion)
TABLE 10. U.S. Human Rabies Vaccines market estimates & forecasts by segment, 2022–2032 (USD Million/Billion)
TABLE 11. Canada Human Rabies Vaccines market estimates & forecasts, 2022–2032 (USD Million/Billion)
TABLE 12. Rest of Europe Human Rabies Vaccines market estimates & forecasts, 2022–2032 (USD Million/Billion)
TABLE 13. China Human Rabies Vaccines market estimates & forecasts, 2022–2032 (USD Million/Billion)
TABLE 14. India Human Rabies Vaccines market estimates & forecasts, 2022–2032 (USD Million/Billion)
TABLE 15. Brazil Human Rabies Vaccines market estimates & forecasts, 2022–2032 (USD Million/Billion)
TABLE 16. Mexico Human Rabies Vaccines market estimates & forecasts, 2022–2032 (USD Million/Billion)
TABLE 17. Saudi Arabia Human Rabies Vaccines market estimates & forecasts, 2022–2032 (USD Million/Billion)
TABLE 18. South Africa Human Rabies Vaccines market estimates & forecasts, 2022–2032 (USD Million/Billion)
TABLE 19. Global Human Rabies Vaccines market, competitive landscape 2023 (market share %)
TABLE 20. Global Human Rabies Vaccines market, pricing analysis by region (2023)
List of Figures
FIGURE 1. Global Human Rabies Vaccines market, research methodology
FIGURE 2. Global Human Rabies Vaccines market, market estimation techniques
FIGURE 3. Global market size estimates & forecast methods
FIGURE 4. Global Human Rabies Vaccines market, key trends 2023
FIGURE 5. Global Human Rabies Vaccines market, growth prospects 2022–2032
FIGURE 6. Global Human Rabies Vaccines market, Porter’s 5 Forces model
FIGURE 7. Global Human Rabies Vaccines market, PESTEL analysis
FIGURE 8. Global Human Rabies Vaccines market, value chain analysis
FIGURE 9. Global Human Rabies Vaccines market by segment, 2022 & 2032 (USD Million/Billion)
FIGURE 10. Global Human Rabies Vaccines market by segment, 2022 & 2032 (USD Million/Billion)
FIGURE 11. Global Human Rabies Vaccines market, regional snapshot 2022 & 2032
FIGURE 12. North America Human Rabies Vaccines market 2022 & 2032 (USD Million/Billion)
FIGURE 13. Europe Human Rabies Vaccines market 2022 & 2032 (USD Million/Billion)
FIGURE 14. Asia Pacific Human Rabies Vaccines market 2022 & 2032 (USD Million/Billion)
FIGURE 15. Latin America Human Rabies Vaccines market 2022 & 2032 (USD Million/Billion)
FIGURE 16. Middle East & Africa Human Rabies Vaccines market 2022 & 2032 (USD Million/Billion)
FIGURE 17. Global Human Rabies Vaccines market, company market share analysis (2023)
FIGURE 18. Global Human Rabies Vaccines market, distribution channel share analysis (2023)
FIGURE 19. Global Human Rabies Vaccines market, pricing trend 2022–2032
FIGURE 20. Global Human Rabies Vaccines market, R&D investment heatmap

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us